-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MaxCyte (NASDAQ:MXCT) Versus Absci (NASDAQ:ABSI) Head-To-Head Analysis
MaxCyte (NASDAQ:MXCT) Versus Absci (NASDAQ:ABSI) Head-To-Head Analysis
MaxCyte (NASDAQ:MXCT – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
Analyst Recommendations
This is a breakdown of recent ratings for MaxCyte and Absci, as provided by MarketBeat.
Get MaxCyte alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
Absci | 2 | 0 | 5 | 0 | 2.43 |
MaxCyte presently has a consensus price target of $11.00, suggesting a potential upside of 85.50%. Absci has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than MaxCyte.
Volatility and Risk
MaxCyte has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Absci has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.Institutional & Insider Ownership
66.4% of MaxCyte shares are owned by institutional investors. Comparatively, 45.4% of Absci shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Comparatively, 19.4% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares MaxCyte and Absci's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MaxCyte | -47.92% | -7.60% | -6.96% |
Absci | -2,223.07% | -29.31% | -25.26% |
Earnings and Valuation
This table compares MaxCyte and Absci's top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MaxCyte | $33.89 million | 17.82 | -$19.08 million | ($0.20) | -29.65 |
Absci | $4.78 million | 77.69 | -$100.96 million | ($1.26) | -3.17 |
MaxCyte has higher revenue and earnings than Absci. MaxCyte is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
Summary
MaxCyte beats Absci on 9 of the 14 factors compared between the two stocks.
About MaxCyte
(Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Absci
(Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
MaxCyte (NASDAQ:MXCT – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
納斯達克(MXCT-GET Rating)和ABSCI(納斯達克:ABSI-GET Rating)都是小盤醫療公司,但哪種投資更好?我們將根據這兩家公司的股息實力、風險、分析師建議、估值、機構所有權、盈利能力和收益進行比較。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings for MaxCyte and Absci, as provided by MarketBeat.
這是MarketBeat提供的MaxCyte和Absci最近的評級細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
Absci | 2 | 0 | 5 | 0 | 2.43 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
Maxcell | 0 | 0 | 1 | 0 | 3.00 |
ABSCI | 2 | 0 | 5 | 0 | 2.43 |
MaxCyte presently has a consensus price target of $11.00, suggesting a potential upside of 85.50%. Absci has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than MaxCyte.
Maxcell目前的共識目標價為11.00美元,這意味着潛在的上行空間為85.50%。Absci的普遍目標價為14.00美元,暗示潛在上行250.00%。鑑於Absci更有可能上行,分析師顯然認為Absci比MaxCyte更有利。
Volatility and Risk
波動性和風險
Institutional & Insider Ownership
機構與內部人持股
66.4% of MaxCyte shares are owned by institutional investors. Comparatively, 45.4% of Absci shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Comparatively, 19.4% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
MaxCyte 66.4%的股份由機構投資者持有。相比之下,ABSCI 45.4%的股份由機構投資者持有。MaxCyte 5.1%的股份由內部人士持有。相比之下,ABSCI 19.4%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一隻股票的長期表現將好於大盤。
Profitability
盈利能力
This table compares MaxCyte and Absci's net margins, return on equity and return on assets.
下表比較了MaxCyte和Absci的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
MaxCyte | -47.92% | -7.60% | -6.96% |
Absci | -2,223.07% | -29.31% | -25.26% |
淨利潤率 | 股本回報率 | 資產回報率 | |
Maxcell | -47.92% | -7.60% | -6.96% |
ABSCI | -2,223.07% | -29.31% | -25.26% |
Earnings and Valuation
收益和估值
This table compares MaxCyte and Absci's top-line revenue, earnings per share and valuation.
該表格比較了MaxCyte和Absci的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MaxCyte | $33.89 million | 17.82 | -$19.08 million | ($0.20) | -29.65 |
Absci | $4.78 million | 77.69 | -$100.96 million | ($1.26) | -3.17 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
Maxcell | 3389萬美元 | 17.82 | -1908萬美元 | ($0.20) | -29.65 |
ABSCI | 478萬美元 | 77.69 | -1.096億元 | ($1.26) | -3.17 |
MaxCyte has higher revenue and earnings than Absci. MaxCyte is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
Maxcell的收入和收益比Absci更高。Maxcell的市盈率低於Absci,表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
MaxCyte beats Absci on 9 of the 14 factors compared between the two stocks.
Maxcell在兩隻股票之間的14個因素中有9個超過了Absci。
About MaxCyte
關於MaxCyte
(Get Rating)
(獲取評級)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Maxcell,Inc.是一家全球生命科學公司,致力於下一代細胞療法的發現、開發和商業化。其產品包括:Expert ATx,一種用於中小規模轉基因的靜態電穿孔儀器;Expert STx,一種用於蛋白質生產和藥物開發的流動電穿孔設備,以及用於基於細胞分析的治療靶點的表達;Expert GTx,一種用於治療應用中大規模轉基因的流動電穿孔設備;以及Expert VLx,用於超大規模細胞工程。該公司還提供用於處理和電穿孔電池的一次性處理組件(PAS);以及支持PAS的配件,如電穿孔緩衝液和軟件協議。該公司成立於1998年,總部設在馬裏蘭州的羅克維爾。
About Absci
關於ABSCI
(Get Rating)
(獲取評級)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSCI公司是一家藥物和靶點發現公司,利用集成的藥物創造平臺為美國的合作伙伴提供生物藥物候選和生產細胞系。其集成的藥物創造平臺通過將藥物發現和細胞系開發過程統一到一個過程中來實現生物製劑的創造。Absci Corporation成立於2011年,總部位於華盛頓州温哥華。
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收MaxCyte日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對MaxCyte和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧